Relmada Therapeutics Inc Share Price OTC Bulletin Board
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
03-19 | Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024 | |
03-19 | Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | 3M 239M | Capitalization | 111M 8.85B |
---|---|---|---|---|---|
Net income 2024 * | -112M -8.93B | Net income 2025 * | -120M -9.57B | EV / Sales 2024 * | - |
Net cash position 2024 * | 203M 16.15B | Net cash position 2025 * | 124M 9.87B | EV / Sales 2025 * | -4.27 x |
P/E ratio 2024 * |
-1.2
x | P/E ratio 2025 * |
-1.56
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.96% |
Latest transcript on Relmada Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Paolo Manfredi
FOU | Founder | 62 | 30/05/12 |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 11/11/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 78 | 13/07/15 | |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 11/11/15 |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |